Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.
about
Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couplesGenital ulcer disease treatment for reducing sexual acquisition of HIVInfectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventionsThe Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the LiteratureIntegrating prevention interventions for people living with HIV into care and treatment programs: a systematic review of the evidence.A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacyDrug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohortsEffects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2Episodic therapy for genital herpes in sub-saharan Africa: a pooled analysis from three randomized controlled trials.Presence of CD8+ T cells in the ectocervical mucosa correlates with genital viral shedding in HIV-infected women despite a low prevalence of HIV RNA-expressing cells in the tissue.Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers.A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk.Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.Stepwise release of biologically active HMGB1 during HSV-2 infection.Correlates of HIV-1 genital shedding in Tanzanian women.Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women.Effect of variable transmission rate on the dynamics of HIV in sub-Saharan Africa.Contribution of sexually transmitted infections to the sexual transmission of HIV.Effect of high versus low oral doses of valacyclovir on herpes simplex virus-1 DNA shedding into tears of latently infected rabbits.Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.Can we reduce the spread of HIV infection by suppressing herpes simplex virus type 2 infection?The Interplay between Sexually Transmitted Infections and HIV: An Evolving StoryHerpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.Effect of genital herpes on cervicovaginal HIV shedding in women co-infected with HIV AND HSV-2 in Tanzania.Effect of treating co-infections on HIV-1 viral load: a systematic reviewGenital HIV-1 RNA predicts risk of heterosexual HIV-1 transmissionGetting research into policy - Herpes simplex virus type-2 (HSV-2) treatment and HIV infection: international guidelines formulation and the case of Ghana.Quantitative and qualitative correlates of cervicovaginal herpes simplex virus type 2 shedding among HIV-infected women in the Women's Interagency HIV Study.Identity of zinc finger nucleases with specificity to herpes simplex virus type II genomic DNA: novel HSV-2 vaccine/therapy precursorsThe role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysisTime to refocus on HSV interventions for HIV prevention?The role of co-infections in mother-to-child transmission of HIV.High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trialCervical HIV-1 RNA shedding after cryotherapy among HIV-positive women with cervical intraepithelial neoplasia stage 2 or 3.Interim modelling analysis to validate reported increases in condom use and assess HIV infections averted among female sex workers and clients in southern India following a targeted HIV prevention programme.Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
P2860
Q21144606-556105C9-A461-4460-B2B3-35510D3FE5A8Q24201630-2BBEEB14-5727-4A7C-8168-17A9375924EAQ26823594-A5B4E1BD-A803-4DC3-B22F-C08B5EF2BE04Q26864344-F7DC0A3D-781C-4312-AE9E-B691571A32B7Q27313271-F0A36D68-C8DF-41A8-90C4-3F2DA743DA7BQ27335068-A8C1FCA2-8102-41B9-9288-E91D92CB027BQ28477883-6088B4FE-AD82-4DE7-822C-3CFA4E5F9710Q28728582-0EBC6E36-C91B-415E-9F14-A762DD56F1BBQ31028568-D634E9D2-9434-4191-8DAC-D966F1B19500Q33390618-CE84F1F3-EE0B-48C9-99B8-1F74BAB292C6Q33436735-98261AEE-90A0-4EE1-A28A-D817743C4470Q33550768-086B7BEA-9DDC-42DF-9362-0DA8B156EB4CQ33609662-D60E76BB-A9EA-48EB-A13A-5A735ABFB684Q33697958-9F34372B-FB49-4338-B6B1-87B98258DC51Q33727305-DC15A0C0-B553-4E67-BFCB-9F0163D8EEE8Q33809521-F5B9F827-318E-44B4-8D69-2EFF8F1E86E3Q33842085-F87047F4-2749-4734-AA6D-47FCE73D418FQ33881449-7C7AD1EA-B556-468E-8E6C-A92815EBFBC6Q33921326-0D60CCD8-D841-4441-883A-62F667E32FC1Q33990906-48DD9243-D8B0-44F3-9337-438DDD381C42Q34071194-405BA9DE-A6AA-423A-90AA-DB0457D88D40Q34135575-1880CE24-AA02-4CAB-8CDB-2DEAD1AD197DQ34168234-CE959E3E-C465-43C2-8DB0-7C8A695562D9Q34175582-21DF8718-C25B-4651-BB4D-3F2A737CADE8Q34196145-C36675C1-650F-4A6C-A4C0-25F8D850F52EQ34508433-C1F69B5B-664F-43A6-BDFD-FB77E97434FAQ34630266-2951C02E-3865-4863-8F41-38E7FB7EA077Q34767216-EFBA94E2-C60C-4841-834F-4361E2107D6CQ34920252-A10BCCCF-84EA-4C0E-870B-554D577022EBQ35062477-14DF8D77-9ACA-4AB5-9973-4A160AB5F008Q35070290-C6B231C8-F685-4981-9B01-752B17F3138FQ35111489-0E842A01-1712-4BBF-BCD6-99D2F7ABBC41Q35149893-2FD38F1C-8DAC-48D2-8509-5D53A6C4DE06Q35532849-8952B64F-C143-4BD4-A148-98A40350B8C5Q35542406-1B73FA8E-1A19-4BBF-8285-A03EF9C1E9C3Q35639207-10643C76-A5EB-40BF-A9E8-8B3062862B9AQ35641646-26050DC3-58DD-42CE-8AA0-0F0410874F62Q35656655-A23428D5-CAAC-484A-8945-D756C947B2CFQ35661728-9B939E4F-6FAB-40E6-8815-73766541C81CQ35669036-249C927A-9262-4D5D-8A51-65FA17266545
P2860
Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Herpes simplex virus (HSV)-sup ...... -controlled, cross-over trial.
@en
Herpes simplex virus (HSV)-sup ...... -controlled, cross-over trial.
@nl
type
label
Herpes simplex virus (HSV)-sup ...... -controlled, cross-over trial.
@en
Herpes simplex virus (HSV)-sup ...... -controlled, cross-over trial.
@nl
prefLabel
Herpes simplex virus (HSV)-sup ...... -controlled, cross-over trial.
@en
Herpes simplex virus (HSV)-sup ...... -controlled, cross-over trial.
@nl
P2093
P2860
P50
P921
P356
P1476
Herpes simplex virus (HSV)-sup ...... -controlled, cross-over trial.
@en
P2093
Amalia Magaret
Jared M Baeten
Jorge Sanchez
Lara B Strick
Robert W Coombs
William L H Whittington
P2860
P304
P356
10.1086/593214
P407
P577
2008-12-01T00:00:00Z